# Evaluate the Efficacy and Safety of KI1106 in Patients Whose TG Level is Not Adequately Controlled With Atorvastatin Calcium Monotherapy While LDL-C is Properly Controlled

Study · id `cardio:ct-nct03482180` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03482180](<https://clinicaltrials.gov/study/NCT03482180>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03482180

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 215 participants.

## Technical summary

Registry record NCT03482180. Randomized; double masking; primary purpose treatment. Start 2016-05-04 (actual); primary completion 2017-05-16 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 215 participants (enrolled count; ClinicalTrials.gov record NCT03482180, source copy `cardio:ctgov-nct03482180-2018-11-19`, retrieved 2026-10-31)
- Started: 2016-05-04 (actual) (ClinicalTrials.gov record NCT03482180, source copy `cardio:ctgov-nct03482180-2018-11-19`, retrieved 2026-10-31)
- Primary completion: 2017-05-16 (actual) (ClinicalTrials.gov record NCT03482180, source copy `cardio:ctgov-nct03482180-2018-11-19`, retrieved 2026-10-31)
- Completion: 2018-03-23 (actual) (ClinicalTrials.gov record NCT03482180, source copy `cardio:ctgov-nct03482180-2018-11-19`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03482180-2018-11-19`, retrieved 2026-10-31)

## The registry's words

- Brief title: Evaluate the Efficacy and Safety of KI1106 in Patients Whose TG Level is Not Adequately Controlled With Atorvastatin Calcium Monotherapy While LDL-C is Properly Controlled
- Condition: Dyslipidemias
- Intervention (Drug): KI1106 4g, QD
- Intervention (Drug): Atorvastatin Calcium 20mg, QD
- Lead sponsor: Kuhnil Pharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)

## Provenance

Content hash: 6be066d3c8bba4d8a1385b54ad09dbd33fba65291dedc61d8b350c0fe8377b4b
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
